 SOUTH SAN FRANCISCO, Calif., Dec. 09, 2020 GLOBE NEWSWIRE -- NGM Biopharmaceuticals, Inc. NGM Nasdaq: NGM, a biotechnology company focused on discovering and developing transformative therapeutics for patients, today disclosed its third oncology development candidate, NGM438, a novel antagonist antibody that inhibits Leukocyte-associated immunoglobulin-like receptor 1 LAIR1. NGM438 was featured earlier today during NGMs first RD Day. The event highlighted the companys diverse portfolio of therapeutic candidates for liver and metabolic disease, retinal diseases and cancer. All presentations from the RD Day can be found in the Investors Media section of NGMs website here. 